Services - Pharmaceutical Launch Excellence
Launching a new healthcare medicine, device or service is one of the most exciting and rewarding things we can do. Our award-winning Pharmaceutical Launch Excellence platform can be customised to companies, brands and markets and has been shown to correlate to superior launch performance.
We can support you in building a structured business plan and can offer diagnostic tools to optimise performance.
LAUNCH STRATEGY
During the early or later pre-launch phases, we can help you create a robust pharmaceutical launch strategy using payer / patient / HCP insights, competitive analysis and a deep understanding of the product profile and market landscape
LAUNCH PLANNING
We love launch planning – we partner with global, regional and local teams to stimulate the creation of world-class launch plans to deliver uptake, positive customer experience and exhilarated launch teams!
LAUNCH READINESS
The process of launch readiness reviews with empowered launch teams, a clear process and indicators of launch readiness can facilitate senior management engagement, discipline and urgency
LAUNCH PERFORMANCE OPTIMISATION
The performance of your launch in the first 3, 6 and 12 months after launch is critical to long term success – how you analyse, engage, track and flex your launch plans during this time will deliver superior uptake
LAUNCH TEAM TRAINING AND MENTORING
Leading a launch is a big leadership task, we can help you with 1:1 or team mentoring sessions to identify your priorities at key phases in the launch, work more effectively and deliver a successful launch
Business Impact: Pharmaceutical Launch Excellence
- Highest launch uptake in Europe for a cardiovascular launch in Greece following a launch readiness and planning project
- Launch readiness reviews across top 10 global countries for an allergy launch resulted in wave 2 countries performing consistently higher than UK, US and German wave 1 countries
- Pharmaceutical Launch Excellence framework, toolkit and resources embedded across 16 countries in Asia-Pacific and LatAm and still in use 7 years later having supported more than 50 new product launches in oncology, pain and respiratory
